Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
AssigneeDinona Inc.
InventorsSeong-Hoe Park, Kyeong-Cheon Jung, Youngmee Bae, Seong-Pyo Park, Yoon-Kyung Jeon
Life of this patent
Estimating the term…
Abstract
The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
Claims11
A monoclonal antibody that binds to human intracellular adhesion molecule 1 (ICAM-1), wherein the antibody is designated MD-2 and is produced by a hybridoma deposited as accession number KCLRF-BP-00198.
A monoclonal antibody that binds to human ICAM-1 comprising a heavy chain and a light chain, the heavy chain comprising three CDRs from the heavy chain of an antibody produced by a hybridoma deposited as accession number KCLRF-BP-00198 and the light chain comprising three CDRs from the light chain of an antibody produced by a hybridoma deposited as accession number KCLRF-BP-00198.
A pharmaceutical composition comprising a monoclonal antibody that binds to human ICAM-1 comprising a heavy chain and a light chain, the heavy chain comprising three CDRs from the heavy chain of an antibody produced by a hybridoma deposited as accession number KCLRF-BP-00198 and the light chain comprising three CDRs from the light chain of an antibody produced by a hybridoma deposited as accession number KCLRF-BP-00198.
A hybridoma producing an antibody, wherein the antibody binds to domain 1 of human intercellular adhesion molecules-1 (ICAM-1), which is deposited as accession number KCLRF-BP-00198.
Dependencies are inferred from the claim text.